Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
DEC-VAC
HIV/AIDS
Framework programme: 6
Call: 3
Project number:
LSHP-CT-2005-018685
EC contribution: € 3 400 000
Duration: 48 months
Type: IP
Starting date: 1st January 2006
Graphic element Development of a Dendritic Cell-targeted Vaccine against AIDS
Keywords: HIV; AIDS; vaccine; dendritic cells; macaques; SIV

Summary:

With support from two successive EU-sponsored consortia, within the Fifth Framework Programme, an in vivo targeting approach has been developed for dendritic cells (DC), which is applicable to protein vaccines, DNA vaccines and viral vector vaccines. Given the urgent need for an HIV vaccine, the potential of this innovative vaccine approach will be evaluated as quickly as possible. Therefore, the aims of the current application of the consortium are to determine the efficacy of dendritic cell-targeted protein-, DNA-, and viral vector vaccines in animal models of HIV/AIDS, and to understand the requirements for and mechanisms of protection.

Background:

Safe, effective and affordable vaccines are needed that elicit the broadest and most robust immune responses against HIV. With the work of this project, these important questions of vaccine research will be addressed. It is planned to use an innovative vaccine developed by the consortium in the macaque model for AIDS. Critical to the success of this innovative vaccine should be its capacity to enhance uptake and presentation of antigens by dendritic cells, which will be analysed by proof of concept studies by the consortium. The project’s strategy to enhance antigen uptake and presentation by DCs can be applied to protein vaccines, peptide vaccines, DNA vaccines and viral vector vaccines, thus providing a broad vaccination platform.

Aim:

The consortium’s mission is to provide a novel HIV vaccine strategy for safety and efficacy studies in humans by the end of the project. Therefore, the scientific and technological objectives of the project are to determine the following for dendritic cell targeted protein, DNA, and viral vector vaccines:

  1. the DC targeting efficacy
  2. the immunogenicity
  3. the efficacy of different adjuvants
  4. the protective properties in the HIV-1/MuLV and SIV macaque model.

Based on these results, the mechanisms of protection will be investigated.

Expected results:

Given the striking positive results in rodent models, this strategy certainly has the potential to be effective and confront the global emergency caused by the spreading HIV epidemic.

Potential applications:

Results from this research effort could lead to the development of a prophylactic or therapeutic HIV/AIDS vaccine. The dendritic cell-targeted vaccine approach could also be useful for the development of vaccines against other infectious diseases and cancer.

Coordinator:

Klaus Überla
Department of Molecular and Medical Virology
Universitätsstr. 150
44780 Bochum

Tel: +49 234 3223189
Fax: +49 234 3214352
E-mail: klaus.ueberla@ruhr-uni-bochum.de
Website: http://www.ruhr-uni-bochum.de/virologie

Partners:

Principal
Scientific
Participants
Official Address Other Information
2
Ralph Steinman
The Rockefeller University
Laboratory of Cellular Physiology and Immunology
1230 York Avenue
10021-6399 New York, N.Y.
United States of America
Tel: +1 212 327 8106
Fax: +1 212 327 8875
E-mail: steinman@rockefeller.edu
3
Britta Wahren
Swedish Institute for Infectious
Disease Control
Department of Virology
Nobels väg 18
SE-171 82 Stockholm
Sweden
Tel: +46 8 4572630
Fax: +46 8 337272
E-mail: britta.wahren@smi.ki.se
4
Christiane Stahl-Hennig
Deutsches Primatenzentrum
Department of Virology and Immunology
Kellnerweg 4
DE-37077 Göttingen
Germany
Tel: +49 551 3851154
Fax: +49 551 3851184
E-mail: stahlh@dpz.gwdg.de
5
Ralf Ignatius
Abt. Med. Mikrobiologie u.
Infektionsimmunologie
Hindenburgdamm 27
DE-12203 Berlin
Germany
Tel: +49 30 84453620
Fax: +49 30 84453830
E-mail: ralf.ignatius@charite.de
6
Paul Racz
Bernhard-Nocht-Institute for
Tropical Medicine
Department of Pathology
Bernhard-Nocht-Str. 74
DE-20359 Hamburg
Germany
Tel: +49 40 42818499
Fax: +49 40 42818544
E-mail: racz@bni.uni-hamburg.de
7
Mariagrazia Uggucioni
Institute for Research in Biomedicine
Via Vincenzo 6
CH-6500 Bellinzona
Switzerland
Tel: +41 91 8200300
Fax: +41 91 8200305
E-mail: mariagrazia.uguccioni@irb.unisi.ch
8
Ralf Wagner
Geneart GmbH,
Josef-Engert-Str. 9
DE-93049 Regensburg
Germany
Tel: +49 941 9427613
Fax: +49 941 9446455
E-mail: ralf.wagner@geneart.com
9
Heribert Stoiber
Innsbruck Medical University
Department of Hygiene, Microbiology
and Social Medicine
Fritz-Pregelstr. 3
AT-6020 Innsbruck
Austria
Tel: +43 512 5973405
Fax: +43 512 5972870
E-mail: heribert.stoiber@uibk.ac.at
10
Lazare Kaptue
University of Yaounde I
Hematology and Immunology Laboratory
P.O. Box 337
Yaounde
Cameroon
Tel: +237 793 42 32
Fax: +237 200 90 75
E-mail: prkaptue@hotmail.com

 
 
top
Graphic element